Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy

AXL overexpression is a common resistance mechanism to anticancer therapies, including the resistance to BYL719 (Alpelisib) — the p110α isoform specific inhibitor of phosphoinositide 3-kinase (PI3K) — in esophagus squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC). Howe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JCI Insight
Hlavní autoři: Badarni, Mai, Prasad, Manu, Balaban, Noa, Zorea, Jonathan, Yegodayev, Ksenia M., Joshua, Ben-Zion, Dinur, Anat Bahat, Grénman, Reidar, Rotblat, Barak, Cohen, Limor, Elkabets, Moshe
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538319/
https://ncbi.nlm.nih.gov/pubmed/30860495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.125341
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky